CoChat

Adjuvant nivolumab in resected stage IIB/C melanoma: primary results from the randomized, phase 3 CheckMate 76K trial

Open access
Kirkwood, John M., Del Vecchio, Michele, Weber, Jeffrey, Hoeller, Christoph, Grob, Jean-Jacques, Mohr, Peter, Loquai, Carmen, Dutriaux, Caroline, Chiarion-Sileni, Vanna, Mackiewicz, Jacek, Rutkowski, Piotr, Arenberger, Petr, Quereux, Gaelle, Meniawy, Tarek M., Ascierto, Paolo A., Menzies, Alexander M., Durani, Piyush, Lobo, Maurice, Campigotto, Federico, Gastman, Brian, Long, Georgina V. · 2023 · Nature Medicine
Cited by 239

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

Abstract

Patients with resected stage IIB/C melanoma have high recurrence risk, similar to those with resected stage IIIA/B disease. The phase 3, double-blind CheckMate 76K trial assessed 790 patients with resected stage IIB/C melanoma randomized 2:1 (stratified by tumor category) to nivolumab 480 mg or placebo every 4 weeks for 12 months. The primary endpoint was investigator-assessed recurrence-free survival (RFS). Secondary endpoints included distant metastasis-free survival (DMFS) and safety. At 7.8 months of minimum follow-up, nivolumab significantly improved RFS versus placebo (hazard ratio (HR) = 0.42; 95% confidence interval (CI): 0.30–0.59; P < 0.0001), with 12-month RFS of 89.0% versus 79.4% and benefit observed across subgroups; DMFS was also improved (HR = 0.47; 95% CI: 0.30–0.72). Treatment-related grade 3/4 adverse events occurred in 10.3% (nivolumab) and 2.3% (placebo) of patients. One treatment-related death (0.2%) occurred with nivolumab. Nivolumab is an effective and generally well-tolerated adjuvant treatment in patients with resected stage IIB/C melanoma. ClinicalTrials.gov identifier: NCT04099251.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41591-023-02583-2

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 4 references

Cited by

See all 239

Metadata

Authors
Kirkwood, J. M., Del Vecchio, M., Weber, J., Hoeller, C., Grob, J.-J., Mohr, P., Loquai, C., Dutriaux, C., Chiarion-Sileni, V., Mackiewicz, J., Rutkowski, P., Arenberger, P., Quereux, G., Meniawy, T. M., Ascierto, P. A., Menzies, A. M., Durani, P., Lobo, M., Campigotto, F., Gastman, B., & Long, G. V.
Venue
Nature Medicine
Published
2023-10-16
Volume
29
Issue
11
Pages
2835-2843
ISSN
  • 1078-8956 (ISSN-L)
  • 1546-170X
OpenAlex
W4387666867
Cited by
239
References
4
FWCI
24.74
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Adjuvant nivolumab in resected stage IIB/C melanoma: primary results from the randomized, phase 3 CheckMate 76K trial. https://app.cochat.ai/papers/10.1038/s41591-023-02583-2
The paper
Kirkwood, J. M., Del Vecchio, M., Weber, J., Hoeller, C., Grob, J.-J., Mohr, P., Loquai, C., Dutriaux, C., Chiarion-Sileni, V., Mackiewicz, J., Rutkowski, P., Arenberger, P., Quereux, G., Meniawy, T. M., Ascierto, P. A., Menzies, A. M., Durani, P., Lobo, M., Campigotto, F., . . . Long, G. V. (2023). Adjuvant nivolumab in resected stage IIB/C melanoma: primary results from the randomized, phase 3 CheckMate 76K trial. Nature Medicine. https://doi.org/10.1038/s41591-023-02583-2

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.